002901.SZ
Double Medical Technology Inc. [002901.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002901.SZ Stock Summary
Top 10 Correlated Stocks
002901.SZ
In the News
002901.SZ Financial details
Company Rating
Neutral
Market Cap
11.94B
Income
58.97M
Revenue
1.53B
Book val./share
7.39
Cash/share
4.01
Dividend
-
Dividend %
-
Employees
3.79K
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-811.84
Forward P/E
-
PEG
228.39
P/S
11.27
P/B
4.84
P/C
7.06
P/FCF
-60.75
Quick Ratio
1.86
Current Ratio
3
Debt / Equity
0.19
LT Debt / Equity
0.08
-
-
EPS (TTM)
0.14
EPS next Y
-
EPS next Q
-
EPS this Y
-36.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-34.49%
Revenue last 5Y
3.85%
Revenue Q/Q
7.17%
EPS Q/Q
-1026.73%
-
-
-
-
SMA20
-3.23%
SMA50
-3.23%
SMA100
-21.05%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-1%
ROC
-
Gross Margin
66%
Oper. Margin
1%
Profit Margin
-1%
Payout
-33%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
23.04-41.96
52W High
-30.98%
52W Low
+23.04%
RSI
43
Rel Volume
0.91
Avg Volume
1.97M
Volume
1.8M
Perf Week
-10.53%
Perf Month
-5.22%
Perf Quarter
-15.97%
Perf Half Y
-20.17%
-
-
-
-
Beta
0.13
-
-
Volatility
0.81%, 1.21%
Prev Close
-0.11%
Price
28.3
Change
-3.38%
002901.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.14 | 3.97 | 4.98 | 3.46 | 3.67 | |
| Net income per share | 1.16 | 1.51 | 1.68 | 0.22 | 0.14 | |
| Operating cash flow per share | 1.08 | 1.39 | 1.68 | 0.31 | 0.21 | |
| Free cash flow per share | 0.29 | 1.05 | 1.09 | -0.38 | -0.53 | |
| Cash per share | 2.31 | 2.67 | 2.94 | 3.26 | 4.01 | |
| Book value per share | 4.3 | 5.26 | 6.27 | 7.25 | 7.39 | |
| Tangible book value per share | 4.27 | 4.99 | 5.91 | 6.99 | 7.26 | |
| Share holders equity per share | 4.3 | 5.26 | 6.27 | 7.25 | 7.39 | |
| Interest debt per share | 0.09 | 0.08 | 0.05 | 0.17 | 1.44 | |
| Market cap | 22.92B | 28.75B | 19.99B | 14.09B | 16.13B | |
| Enterprise value | 22.19B | 28.22B | 19.6B | 13.16B | 15.51B | |
| P/E ratio | 49.24 | 47.47 | 29.69 | 152.22 | 273.59 | |
| Price to sales ratio | 18.23 | 18.12 | 10.02 | 9.82 | 10.62 | |
| POCF ratio | 52.83 | 51.73 | 29.7 | 109.69 | 188.07 | |
| PFCF ratio | 200.03 | 68.68 | 45.63 | -89.95 | -73.36 | |
| P/B Ratio | 13.31 | 13.67 | 7.96 | 4.7 | 5.28 | |
| PTB ratio | 13.31 | 13.67 | 7.96 | 4.7 | 5.28 | |
| EV to sales | 17.65 | 17.78 | 9.83 | 9.18 | 10.21 | |
| Enterprise value over EBITDA | 36.54 | 36.58 | 21.83 | 51.42 | 76.69 | |
| EV to operating cash flow | 51.15 | 50.78 | 29.11 | 102.5 | 180.75 | |
| EV to free cash flow | 193.66 | 67.41 | 44.74 | -84.05 | -70.51 | |
| Earnings yield | 0.02 | 0.02 | 0.03 | 0.01 | 0 | |
| Free cash flow yield | 0 | 0.01 | 0.02 | -0.01 | -0.01 | |
| Debt to equity | 0.02 | 0.02 | 0.01 | 0.02 | 0.19 | |
| Debt to assets | 0.02 | 0.01 | 0.01 | 0.02 | 0.13 | |
| Net debt to EBITDA | -1.2 | -0.69 | -0.44 | -3.61 | -3.1 | |
| Current ratio | 3.87 | 4.47 | 3.32 | 3.8 | 2.74 | |
| Interest coverage | 6.2K | 5.01K | 1.5K | 47.61 | 1.09 | |
| Income quality | 0.91 | 0.9 | 0.97 | 1.18 | 1.45 | |
| Dividend Yield | 0.01 | 0.01 | 0.02 | 0.01 | 0 | |
| Payout ratio | 0.44 | 0.42 | 0.48 | 2.26 | 0.16 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | |
| Research and developement to revenue | 0.08 | 0.08 | 0.08 | 0.18 | 0.18 | |
| Intangibles to total assets | 0.02 | 0.05 | 0.06 | 0.05 | 0.04 | |
| Capex to operating cash flow | -0.74 | -0.25 | -0.35 | -2.22 | -3.56 | |
| Capex to revenue | -0.25 | -0.09 | -0.12 | -0.2 | -0.2 | |
| Capex to depreciation | -8.02 | -2.72 | -3.32 | -2.98 | -1.57 | |
| Stock based compensation to revenue | 0 | 0 | 0.02 | 0.08 | -0.4 | |
| Graham number | 10.61 | 13.38 | 15.39 | 6.04 | 4.87 | |
| ROIC | 0.27 | 0.29 | 0.28 | 0.04 | 0 | |
| Return on tangible assets | 0.21 | 0.24 | 0.21 | 0.02 | 0.01 | |
| Graham Net | 2.15 | 2.7 | 2.74 | 3.13 | 2.5 | |
| Working capital | 1.22B | 1.53B | 1.67B | 2.01B | 2B | |
| Tangible asset value | 1.71B | 1.99B | 2.37B | 2.89B | 3.01B | |
| Net current asset value | 1.16B | 1.47B | 1.6B | 1.9B | 1.73B | |
| Invested capital | 0.02 | 0.02 | 0.01 | 0.02 | 0.19 | |
| Average receivables | 178.56M | 294.5M | 413.61M | 436.28M | 324.39M | |
| Average payables | 125.5M | 195.46M | 238.06M | 320.83M | 313.5M | |
| Average inventory | 360.79M | 499.57M | 606.09M | 828.75M | 1.09B | |
| Days sales outstanding | 75.45 | 75.7 | 91.16 | 95.31 | 65.93 | |
| Days payables outstanding | 425.87 | 292.73 | 347.68 | 377.51 | 194.77 | |
| Days of inventory on hand | 922.23 | 882.29 | 786.37 | 1.08K | 825.21 | |
| Receivables turnover | 4.84 | 4.82 | 4 | 3.83 | 5.54 | |
| Payables turnover | 0.86 | 1.25 | 1.05 | 0.97 | 1.87 | |
| Inventory turnover | 0.4 | 0.41 | 0.46 | 0.34 | 0.44 | |
| ROE | 0.27 | 0.29 | 0.27 | 0.03 | 0.02 | |
| Capex per share | -0.8 | -0.34 | -0.59 | -0.69 | -0.74 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.48 | 0.94 | 0.87 | 0.91 | 0.97 | |
| Net income per share | -0.28 | 0.14 | 0.09 | 0.01 | -0.09 | |
| Operating cash flow per share | -0.28 | 0.14 | 0.11 | 0.16 | 0.17 | |
| Free cash flow per share | -0.46 | -0.03 | -0.11 | 0.02 | -0.03 | |
| Cash per share | 3.24 | 3.1 | 3.43 | 3.74 | 4.01 | |
| Book value per share | 7.19 | 7.33 | 7.47 | 7.48 | 7.39 | |
| Tangible book value per share | 6.94 | 7.09 | 7.21 | 7.25 | 7.26 | |
| Share holders equity per share | 7.19 | 7.33 | 7.47 | 7.48 | 7.39 | |
| Interest debt per share | 0.17 | 0.43 | 0.87 | 1.16 | 1.43 | |
| Market cap | 14.2B | 15.14B | 12.87B | 13.47B | 16.13B | |
| Enterprise value | 13.27B | 14.4B | 12.17B | 12.87B | 15.51B | |
| P/E ratio | -30.55 | 65.02 | 91.06 | 805.39 | -104.11 | |
| Price to sales ratio | 71.25 | 38.68 | 35.92 | 35.84 | 40.06 | |
| POCF ratio | -122.19 | 260.06 | 290.23 | 199.62 | 234.55 | |
| PFCF ratio | -73.51 | -1.06K | -277.15 | 1.65K | -1.13K | |
| P/B Ratio | 4.73 | 4.95 | 4.16 | 4.35 | 5.28 | |
| PTB ratio | 4.73 | 4.95 | 4.16 | 4.35 | 5.28 | |
| EV to sales | 66.61 | 36.79 | 33.98 | 34.25 | 38.5 | |
| Enterprise value over EBITDA | -124.35 | 190.62 | 317.65 | 688.73 | -1.79K | |
| EV to operating cash flow | -114.23 | 247.35 | 274.58 | 190.76 | 225.43 | |
| EV to free cash flow | -68.73 | -1K | -262.2 | 1.57K | -1.08K | |
| Earnings yield | -0.01 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | -0.01 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.02 | 0.06 | 0.12 | 0.15 | 0.19 | |
| Debt to assets | 0.02 | 0.04 | 0.08 | 0.11 | 0.13 | |
| Net debt to EBITDA | 8.66 | -9.8 | -18.11 | -31.99 | 72.39 | |
| Current ratio | 3.8 | 4.2 | 3.34 | 3 | 2.74 | |
| Interest coverage | -47.45 | 222.15 | 35.61 | 12.35 | -17.35 | |
| Income quality | 1 | 1 | 1.26 | 16.14 | -1.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.01 | 0.05 | 0.72 | -0.1 | |
| Sales general and administrative to revenue | -0.28 | 0.07 | -0.04 | 0.2 | -0.14 | |
| Research and developement to revenue | 0.35 | 0.16 | 0.17 | 0.18 | 0.22 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | |
| Capex to operating cash flow | 0.66 | -1.25 | -2.05 | -0.88 | -1.21 | |
| Capex to revenue | -0.39 | -0.19 | -0.25 | -0.16 | -0.21 | |
| Capex to depreciation | -3.57 | -1.59 | -1.99 | 1.06 | -1.61 | |
| Stock based compensation to revenue | 0.55 | 0 | 0 | 0 | 0 | |
| Graham number | 6.71 | 4.8 | 3.79 | 1.3 | 3.94 | |
| ROIC | -0.04 | 0.02 | 0.01 | 0.01 | -0.02 | |
| Return on tangible assets | -0.03 | 0.02 | 0.01 | 0 | -0.01 | |
| Graham Net | 3.1 | 3.03 | 2.76 | 2.65 | 2.5 | |
| Working capital | 2.01B | 2.08B | 2.05B | 2.05B | 2B | |
| Tangible asset value | 2.89B | 2.96B | 2.98B | 3B | 3.01B | |
| Net current asset value | 1.9B | 1.88B | 1.81B | 1.79B | 1.73B | |
| Invested capital | 0.02 | 0.06 | 0.12 | 0.15 | 0.19 | |
| Average receivables | 461.72M | 397.41M | 413.47M | 384.26M | 318.14M | |
| Average payables | 348.02M | 331.4M | 317.37M | 318.93M | 301.1M | |
| Average inventory | 942.02M | 997.73M | 1.04B | 1.11B | 1.17B | |
| Days sales outstanding | 169.15 | 96.67 | 102.13 | 86.68 | 61.3 | |
| Days payables outstanding | 351.05 | 240.94 | 262.64 | 204.67 | 190.41 | |
| Days of inventory on hand | 1K | 765.16 | 894.6 | 730.1 | 806.72 | |
| Receivables turnover | 0.53 | 0.93 | 0.88 | 1.04 | 1.47 | |
| Payables turnover | 0.26 | 0.37 | 0.34 | 0.44 | 0.47 | |
| Inventory turnover | 0.09 | 0.12 | 0.1 | 0.12 | 0.11 | |
| ROE | -0.04 | 0.02 | 0.01 | 0 | -0.01 | |
| Capex per share | -0.18 | -0.17 | -0.22 | -0.14 | -0.2 |
002901.SZ Frequently Asked Questions
What is Double Medical Technology Inc. stock symbol ?
Double Medical Technology Inc. is a CN stock and trading under the symbol 002901.SZ
What is Double Medical Technology Inc. stock quote today ?
Double Medical Technology Inc. stock price is $28.3 today.
Is Double Medical Technology Inc. stock public?
Yes, Double Medical Technology Inc. is a publicly traded company.
Company Profile
- Volume Average 1.97M
- Market Capitalization 11.94B
- Employee 3.79K
- CEO Mr. Jiong Luo
- Headquarters Xiamen,CN
- IPO Date 2017-09-22
-
Website
https://www.double-medical.com 
Double Medical Technology Inc. provides services, technologies, and devices in the areas of orthopedics, wound management, neurosurgery, and general surgery in China. It also exports its products to approximately 50 countries and regions, including European Union, Russia, South America, Australia, Southeast Asia, the Middle East, and South Africa. The company was formerly known as Xiamen Da Bo Ying Jing Medical Equipment Company Limited. Double Medical Technology Inc. was founded in 2004 and is based in Xiamen, the People's Republic of China.
